TriangleADV/HSV-tk (gene therapy) (NCT03596086)
ADV/HSV-tk (gene therapy) trial for Recurrent Glioblastoma or Grade III Astrocytoma (NCT03596086). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for glioblastoma or grade three astrocytoma that has come back after standard treatment, in adults.
The idea: add gene therapy to radiation. A gene called HSV-tk is injected during surgery. Within a day, patients start valacyclovir, an antiviral drug, for 14 days. Radiotherapy follows, along with chemotherapy. People with multifocal tumors or brainstem involvement are not included.
This phase 1 and 2 study plans 62 patients and measures survival from the day of treatment. At Houston Methodist in Texas, David Baskin leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.